CLL Topics Banner: Therapies, Research and Patient Education for Chronic Lymphocytic Leukemia
CLL Topics Home Navigation Topics Alert Learning Tools About Us Feedback Feedback
Full Menu

Topics Alert

  • el
  • pt
  • world balloon

    Topics Alert Archive

    Alert Number 12

    LMB-2 in Phase - II Trial Sponsored by NCI

    Date: April 13, 2024

    Novel Application of a New Anti-CD25 immunotoxin Offers Prospects of Highly Targeted and Effective Therapy.

    We report on the recently announced clinical trial of a new immunotoxin, LMB-2, which shows early promise in attacking CLL cells. The technology has great potential if it is used in combination with immunomodulators such as bacterial-DNA derived CpG-ODN to up-regulate CD25, improving targeting of B-CLL cells. We discuss the background, results from early trials and the potential for effective treatment with low toxicity using this agent.

    Here is the link to this just-published article:LMB-2.

    Be well,

    Chaya
    _____

    NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.


    Go to Alert Archive Listing

    You may also retrieve a different Alert,
    by entering a new Alert number here
    (in the range 1 to 309)

     

    ———

    Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.


    Copyright Notice:

    Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.

    All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.

    However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.

    ———

    crest

     

    GuideCompass
    up arrow